Lung cancer patients with bone metastasis generally belong to the advanced stage, and the 5-year survival rate is 5%. At this time, if they are able to apply targeted therapy, the survival period may be extended by more than 2~5 years, which varies from person to person, and cannot be generalized. Among lung cancer patients, some of them are related to gene mutations, and there are currently targeted drugs that specifically target these mutations. Targeted drugs can kill cancer cells with no or less damage to normal tissue cells. There is obvious progress in the treatment of lung cancer bone metastasis with targeted drugs, and the survival period of patients with standardized treatment can be extended by more than 2~5 years. The prognosis of lung cancer patients depends on whether they can be detected early, diagnosed early and treated timely and reasonably. It is suggested that patients with bone metastasis of lung cancer can alleviate the symptoms, improve the quality of life and prolong the survival period through active treatment.